Very early diagnosis of systemic sclerosis

Polskie Archiwum Medycyny Wewnetrznej

Volumn 122, Issue SUPPL.1, 2012, Pages 18-23

  Bellando Randone, Silvia ^a   Guiducci, Serena ^a   Matucci Cerinic, Marco ^b  

^a CAREGGI UNIVERSITY HOSPITAL   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Early diagnosis; Raynaud's phenomenon; Systemic sclerosis

Indexed keywords

CENTROMERE ANTIBODY; DNA TOPOISOMERASE;

ATROPHY; CAPILLAROSCOPY; CLINICAL FEATURE; DELPHI STUDY; EARLY DIAGNOSIS; FIBROSIS; FINGER ULCER; HEART VENTRICLE TACHYCARDIA; HUMAN; INTERSTITIAL LUNG DISEASE; KIDNEY FAILURE; MORBIDITY; MORTALITY; NUCLEAR MAGNETIC RESONANCE IMAGING; PREDICTION; PROGNOSIS; PULMONARY HYPERTENSION; RAYNAUD PHENOMENON; REVIEW; SYSTEMIC SCLEROSIS;

EID: 84872819420     PISSN: 00323772     EISSN: None     Source Type: Journal    
DOI: 10.20452/pamw.1487     Document Type: Review

References (50)

1. Chifflot H, Fautrel B, Sordet C, et al. Incidence and prevalence of systemic sclerosis: a systematic literature review. Semin Arhritis Rheum. 2008; 37: 223-235.
2. Mayes MD. Scleroderma epidemiology. Rheum Dis Clin North Am. 2003; 29: 239-254.
3. Mayes MD, Lacey JV, Beebe-Dimmer J, et al. Prevalence, incidence, survival and disease characteristics of systemic sclerosis in a large US population. Arthritis Rheum. 2003; 48: 2246-2255.
4. Assassi S, Del Junco D, Sutter K, et al. Clinical and genetic factors predictive of mortality in early systemic sclerosis Arthritis Rheum. 2009; 61: 1403-1411.
5. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum. 1980; 23: 581-590.
6. LeRoy EC, Medsger TA Jr. Criteria for the classification of early systemic sclerosis. J Rheumatol. 2001; 28: 1573-1576.
7. Koenig M, Joyal F, Fritzler MJ, et al. Autoantibodies and microvascular damage are independent predictive factors for the progression of Raynaud's phenomenon to systemic sclerosis: a twenty-year prospective study of 586 patients, with validation of proposed criteria for early systemic sclerosis. Arthritis Rheum. 2008; 58: 3902-3912.
8. Lonzetti LS, Joyal F, Raynauld J P, et al. Updating the American College of Rheumatology preliminary classification criteria for systemic sclerosis: addition of severe nailfold capillaroscopy abnormalities markedly increases the sensitivity for limited scleroderma. Arthritis Rheum. 2001; 44: 735-736.
9. Walker UA, Tyndall A, Czirják L, et al. Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database. Ann Rheum Dis. 2007; 66: 754-763.
10. Hudson M, Taillefer S, Steele R, et al. Improving the sensitivity of the American College of Rheumatology classification criteria for systemic sclerosis. Clin Exp Rheumatol. 2007; 25: 754-757.
11. Czirják L, Matucci-Cerinic M. Beyond Raynaud's phenomenon hides very early systemic sclerosis: the assessment of organ involvement is always mandatory. Rheumatology (Oxford). 2011; 50: 250-251.
12. Del Rosso A, Boldrini M, D'Agostino D, et al Health-related quality of life in systemic sclerosis as measured by the Short Form 36: relationship with clinical and biologic markers. Arthritis Rheum. 2004; 51: 475-481.
13. Valentini G, Matucci-Cerinic M. Disease-specific quality indicators, guidelines and outcome measures in scleroderma. Clin Exp Rheumatol. 2007; 25 (6 Suppl 47): 159-162.
14. Matucci-Cerinic M, Allanore Y, Czirják L, et al. The challenge of early systemic sclerosis for the EULAR Scleroderma Trial and Research group (EUSTAR) community. It is time to cut the Gordian knot and develop a prevention or rescue strategy. Ann Rheum Dis. 2009; 68: 1377-1380.
15. Avouac J, Fransen J, Walker UA, et al. Preliminary criteria for the very early diagnosis of systemic sclerosis: results of a Delphi Consensus Study from EULAR Scleroderma Trials and Research Group. Ann Rheum Dis. 2011; 70: 476-481.
16. Denton C P, Black CM, Korn JH, de Crombrugghe B. Systemic sclerosis: current pathogenetic concepts and future prospects for targeted therapy. Lancet. 1996; 347: 1453-1458.
17. LeRoy EC, Maricq HR, Kahaleh MB. Undifferentiated connective tissue syndromes. Arthritis Rheum. 1980; 23: 341-343.
18. Lundberg IE. The prognosis of mixed connective tissue disease. Rheum Dis Clin North Am. 2005; 31: 535-547.
19. Matucci-Cerinic M, Steen V, Nash P, Hachulla E. The complexity of managing systemic sclerosis: screening and diagnosis. Rheumatology (Oxford). 2009; 48 (Suppl 3): iii8-iii13.
20. Hirschl M, Hirschl K, Lenz M, et al. Transition from primary Raynaud's phenomenon to secondary Raynaud's phenomenon identified by diagnosis of an associated disease: results of ten years of prospective surveillance. Arthritis Rheum. 2006; 54: 1974-1981.
21. Kowal-Bielecka O, Landewé R, Avouac J, et al. EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis. 2009; 68: 620-628.
22. Valentini G, Cuomo G, Abignano G, et al. Early systemic sclerosis: assessment of clinical and pre-clinical organ involvement in patients with different disease features. Rheumatology (Oxford). 2011; 50: 317-323.
23. Varga J, Abraham D. Systemic sclerosis: a prototypic multisystem fibrotic disorder. J Clin Invest. 2007; 117: 557-567.
24. Denton C P, Lapadula G, Mouthon L, Müller-Ladner U. Renal complications and scleroderma renal crisis. Rheumatology (Oxford). 2009; 48 (Suppl 3): iii32-iii35.
25. Latsi PI, Wells AU. Evaluation and management of alveolitis and interstitial lung disease in scleroderma. Curr Opin Rheumatol. 2003; 15: 748-755.
26. Steen VD, Medsger TA Jr. Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum. 2000; 43: 2437-2444.
27. Steen VD, Medsger TA. Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis. 2007; 66: 940-944.
28. Hachulla E, Gressin V, Guillevin L, et al. Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study. Arthritis Rheum. 2005; 52: 3792-3800.
29. Diot E, Giraudeau B, Diot P, et al. Is anti-topoisomerase I a serum marker of pulmonary involvement in systemic sclerosis? Chest. 1999; 116: 715-720.
30. Mukerjee D, St George D, Coleiro B, et al. Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann Rheum Dis. 2003; 62: 1088-1093.
31. Humbert M, Sitbon O, Chaouat A, et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med. 2006; 173: 1023-1030.
32. MacGregor AJ, Canavan R, Knight C, et al. Pulmonary hypertension in systemic sclerosis: risk factors for progression and consequences for survival. Rheumatology (Oxford). 2001; 40: 453-459.
33. Meune C, Avouac J, Airò P, et al. Prediction of pulmonary hypertension related to systemic sclerosis by an index based on simple clinical observations. Arthritis Rheum. 2011; 63: 2790-2796.
34. Allanore Y, Borderie D, Avouac J, et al. High N-terminal pro-brain natriuretic peptide levels and low diffusing capacity for carbon monoxide as independent predictors of the occurrence of precapillary pulmonary arterial hypertension in patients with systemic sclerosis. Arthritis Rheum. 2008; 58: 284-291.
35. Andreassen AK, Wergeland R, Simonsen S, et al. N-terminal pro-B-type natriuretic peptide as an indicator of disease severity in a heterogeneous group of patients with chronic precapillary pulmonary hypertension. Am J Cardiol. 2006; 98: 525-529.
36. Alivernini S, De Santis M, Tolusso B, et al. Skin ulcers in systemic sclerosis: determinants of presence and predictive factors of healing. J Am Acad Dermatol. 2009; 60: 426-435.
37. Wigley FM, Korn JH, Csuka ME, et al. Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study. Arthritis Rheum. 1998; 41: 670-677.
38. Pope JE, Bellamy N. Sample size calculations in scleroderma: a rational approach to choosing outcome measurements in scleroderma trials. Clin Invest Med. 1995; 18: 1-10.
39. Della Rossa A, Valentini G, Bombardieri S, et al. European multicentre study to define disease activity criteria for systemic sclerosis. I. Clinical and epidemiological features of 290 patients from 19 centres. Ann Rheum Dis. 2001; 60: 585-591.
40. Chifflot H, Fautrel B, Sordet C, et al. Incidence and prevalence of systemic sclerosis: a systematic literature review. Semin Arthritis Rheum. 2008; 37: 223-235.
41. Ingegnoli F, Boracchi P, Gualtierotti R, et al. Prognostic model based on nailfold capillaroscopy for identifying Raynaud's phenomenon patients at high risk for the development of a scleroderma spectrum disorder: PRINCE (prognostic index for nailfold capillaroscopic examination). Arthritis Rheum. 2008; 58: 2174-2182.
42. Cutolo M, Matucci Cerinic M. Nailfold capillaroscopy and classification criteria for systemic sclerosis. Clin Exp Rheumatol. 2007; 25: 663-665.
43. Sebastiani M, Manfredi A, Colaci M, et al. Capillaroscopic skin ulcer risk index: a new prognostic tool for digital skin ulcer development in systemic sclerosis patients. Arthritis Rheum. 2009; 61: 688-694.
44. Follansbee W P. The cardiovascular manifestations of systemic sclerosis (scleroderma). Curr Probl Cardiol. 1986; 11: 241-298.
45. Kostis JB, Seibold JR, Turkevich D, et al. Prognostic importance of cardiac arrhythmias in systemic sclerosis. Am J Med. 1988; 84: 1007-1015.
46. Clements PJ, Furst DE, Cabeen W, et al. The relationship arrhythmias and conduction disturbances to other manifestations of cardiopulmonary disease in progressive systemic sclerosis (PSS). Am J Med. 1981; 71: 38-46.
47. Smith JW, Clements PJ, Levisman J, et al. Echocardiographic features of progressive systemic sclerosis (PSS): correlation with hemodynamic and postmortem studies. Am J Med. 1979; 66: 28-33.
48. Clements PJ. Systemic sclerosis (scleroderma) and related disorders: clinical aspects. Baillieres Best Pract Res Clin Rheumatol. 2000; 14: 1-16.
49. Champion HC. The heart in scleroderma. Rheum Dis Clin North Am. 2008; 34: 181-190; viii.
50. Hachulla AL, Launay D, Gaxotte V, et al. Cardiac magnetic resonance imaging in systemic sclerosis: a cross-sectional observational study of 52 patients. Ann Rheum Dis. 2009; 68: 1878-1884.